Similar articles for PMID: 29664454

Year	Number of Results
2010	1
2011	1
2012	1
2013	2
2014	11
2015	15
2016	26
2017	22
2018	17
2019	17
2020	22
2021	28
2022	19
2023	3
2024	0

1

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran.

Ouspid E, Razazian N, Moghadasi AN, Moradian N, Afshari D, Bostani A, Sariaslani P, Ansarian A. Ouspid E, et al. Neurosciences (Riyadh). 2018 Apr;23(2):129-134. doi: 10.17712/nsj.2018.2.20170434. Neurosciences (Riyadh). 2018. PMID: 29664454 Free PMC article. Clinical Trial.

2

Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.

Tichá V, Kodým R, Počíková Z, Kadlecová P. Tichá V, et al. Clin Drug Investig. 2017 Feb;37(2):175-186. doi: 10.1007/s40261-016-0471-2. Clin Drug Investig. 2017. PMID: 27785735 Free PMC article.

3

The effectiveness of fingolimod in a Portuguese real-world population.

Correia I, Batista S, Marques IB, Sousa M, Ferreira R, Nunes C, Macário MC, Sousa L. Correia I, et al. Mult Scler Relat Disord. 2016 Mar;6:41-48. doi: 10.1016/j.msard.2016.01.003. Epub 2016 Jan 12. Mult Scler Relat Disord. 2016. PMID: 27063621 Clinical Trial.

4

A longitudinal real-life comparison study of natalizumab and fingolimod.

Lanzillo R, Carotenuto A, Moccia M, Saccà F, Russo CV, Massarelli M, De Rosa A, Brescia Morra V. Lanzillo R, et al. Acta Neurol Scand. 2017 Sep;136(3):217-222. doi: 10.1111/ane.12718. Epub 2016 Dec 15. Acta Neurol Scand. 2017. PMID: 27976804

5

Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).

Alroughani R, AlKawi Z, Hassan A, Al Otaibi H, Mujtaba A, Al Atat R, Riachi N, Akkawi N, Koussa S, Inshasi J, Alsaadi T, Ahmed SF, Al-Aasmi A, Zakaria M, El Fadally H. Alroughani R, et al. Clin Neurol Neurosurg. 2021 Apr;203:106576. doi: 10.1016/j.clineuro.2021.106576. Epub 2021 Feb 25. Clin Neurol Neurosurg. 2021. PMID: 33714799

6

Fingolimod for relapsing-remitting multiple sclerosis.

La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G. La Mantia L, et al. Cochrane Database Syst Rev. 2016 Apr 19;4(4):CD009371. doi: 10.1002/14651858.CD009371.pub2. Cochrane Database Syst Rev. 2016. PMID: 27091121 Free PMC article. Review.

7

[Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].

Alcala-Vicente C, Perez-Miralles FC, Gascon-Gimenez F, Bosca-Blasco I, Navarre-Gimeno A, Coret-Ferrer F, Casanova-Estruch B. Alcala-Vicente C, et al. Rev Neurol. 2017 May 16;64(10):445-453. Rev Neurol. 2017. PMID: 28497440 Free article. Spanish.

8

Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.

Rezaee M, Izadi S, Keshavarz K, Borhanihaghighi A, Ravangard R. Rezaee M, et al. J Med Econ. 2019 Apr;22(4):297-305. doi: 10.1080/13696998.2018.1560750. Epub 2019 Jan 8. J Med Econ. 2019. PMID: 30561242 Free article.

9

Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.

Puz P, Lasek-Bal A. Puz P, et al. Med Sci Monit. 2016 Nov 10;22:4277-4282. doi: 10.12659/msm.898270. Med Sci Monit. 2016. PMID: 27829656 Free PMC article.

10

Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.

Algahtani H, Shirah B, Al Malik Y, Meftah I. Algahtani H, et al. Clin Neuropharmacol. 2020 Mar/Apr;43(2):35-38. doi: 10.1097/WNF.0000000000000378. Clin Neuropharmacol. 2020. PMID: 32106137

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

152 results

Results by year